Investment Rating - The report initiates coverage on Aosaikang with a "Buy" rating [5][7]. Core Views - Aosaikang is experiencing a turning point in operations, with a forecasted return to profitability in the first half of 2024 due to the clearance of centralized procurement and the launch of new products [5][20]. - The company is transitioning towards innovation, with significant progress in drug development, particularly in the areas of third-generation EGFR inhibitors and Claudin18.2 [5][17]. Summary by Sections 1. Company Overview - Aosaikang, a leader in the digestive field, has faced challenges since 2019 due to centralized procurement and the COVID-19 pandemic, leading to a significant decline in revenue [17][20]. - The company is now poised for recovery, with innovative drugs expected to contribute positively to future performance [5][17]. 2. Traditional Business - The digestive business has been significantly impacted by centralized procurement, with revenue dropping from 33.7 billion in 2019 to 3 billion in 2023 [5][31]. - New products, such as Right Lansoprazole, are expected to drive revenue growth in the digestive segment [33]. - The oncology segment has seen a revenue decline from 10.2 billion in 2019 to 6.2 billion in 2023, but its revenue share is increasing due to the sharper decline in the digestive segment [35]. 3. Innovative Transformation - Aosaikang has partnered with Innovent to commercialize third-generation EGFR inhibitors, which are expected to achieve rapid market penetration [5][17]. - The company is advancing in the development of Claudin18.2 and IL-15 prodrugs, which are seen as promising therapeutic targets in oncology [5][3]. 4. Financial Forecast and Investment Recommendations - Revenue projections for Aosaikang are 16.7 billion, 19 billion, and 23.4 billion for 2024, 2025, and 2026, respectively, indicating a recovery trajectory [5][6]. - The company’s price-to-sales (P/S) ratio is below the average of comparable companies, suggesting potential undervaluation [5].

Investment Rating - The report maintains a "Buy" rating for the company [7]. Core Views - The company reported a revenue of 1.38 billion yuan for the first three quarters of 2024, representing a year-on-year growth of 23.6%. The net profit attributable to shareholders was 130 million yuan, marking a turnaround from losses [3][4]. - The sales of existing products are performing well, leading to an upward revision of the 2024 revenue forecast to 1.79 billion yuan from the previous estimate of 1.66 billion yuan [4]. - The company has a healthy cash flow with over 2 billion yuan in cash on hand as of September 30, 2024. R&D expenses have significantly decreased to 170 million yuan, a 60% reduction year-on-year, as key clinical phases for several new drugs have been completed [4]. - The clinical progress of ophthalmic drugs is steady, with ASKG712 being the second global VEGF/ANG2 ophthalmic drug to enter clinical trials. It has completed Phase I studies and is currently in Phase IIa for treating nAMD and DME [5]. - The company is expected to achieve net profits of 196 million yuan, 246 million yuan, and 367 million yuan for 2024-2026, with corresponding EPS of 0.21 yuan, 0.27 yuan, and 0.40 yuan [5]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a total revenue of 1.38 billion yuan, with a single-quarter revenue of 460 million yuan in Q3, reflecting a year-on-year increase of 13.2% [3][4]. - The net profit for Q3 was 51 million yuan, showing a quarter-on-quarter increase [3]. Product Development - The company is advancing its innovative drug pipeline, with ASK120067 in the NDA stage and ASKC109 and ASKB589 in Phase III trials. These drugs are expected to be approved in the next 2-3 years, ensuring healthy future cash flows [4]. - The clinical development of ASKG712 is progressing well, with significant advantages in patient compliance due to reduced dosing frequency [5]. Market Position - The company has maintained a strong market position with its existing products, particularly in the categories of Nedaplatin and Right Levosimendan, which have not entered the tenth batch of centralized procurement [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 17.86 yuan, reflecting a reasonable market value of 165.75 billion yuan [2][4]. Core Insights - The company achieved significant revenue growth, with a reported income of 1.384 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 23.64%. The net profit attributable to the parent company reached 127 million yuan, up 168.79% year-on-year [1]. - The company is in a rapid development phase of innovation, with key clinical pipelines advancing, including a Claudin18.2 monoclonal antibody for gastric cancer in phase III trials and a third-generation EGFR-TKI awaiting approval [1]. - The impact of the tenth batch of centralized procurement is expected to be manageable, with the historical effects largely mitigated and new products enhancing market competitiveness [1]. Financial Performance Summary - The company’s revenue for 2024 is projected to be 1.751 billion yuan, with a year-on-year growth of 21.3%. The net profit attributable to the parent company is expected to be 162 million yuan, reflecting a growth of 209.1% [3]. - The gross margin is forecasted to be 80.5% in 2024, with a net margin of 9.3% [3]. - The earnings per share (EPS) is projected to be 0.17 yuan for 2024, increasing to 0.40 yuan by 2026 [3].

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company has achieved a turnaround in its net profit, with a significant increase in revenue and profit margins, indicating a positive growth trajectory [2][3]. - The rapid growth in the anti-infection and chronic disease segments, along with the anticipated success of innovative drug applications, positions the company favorably for future performance [4]. Summary by Sections Financial Performance - In the first three quarters of 2024, the company reported revenue exceeding 1.38 billion yuan, a year-on-year increase of 23.6%. The net profit attributable to shareholders reached nearly 130 million yuan, up 168.8% year-on-year, with a non-recurring net profit of over 100 million yuan, reflecting a 145.6% increase [2]. - For Q3 2024, the company achieved revenue of 460 million yuan, a year-on-year increase of 13.2%, and a net profit of 51.42 million yuan, marking a 296.3% increase year-on-year and a 16.7% increase quarter-on-quarter [2]. Product Segmentation - The company's revenue is primarily derived from four segments: anti-infection, anti-tumor, chronic disease, and digestive products, with the first half of 2024 seeing over 96.9% of total revenue from the first three segments. Specifically, anti-infection revenue was 260 million yuan (up 132.31% YoY), anti-tumor revenue exceeded 330 million yuan (up 7.54% YoY), and chronic disease revenue was 160 million yuan (up 60.2% YoY) [2]. Cost Management and Profitability - The company's operating costs for the first three quarters of 2024 were 250 million yuan, a year-on-year increase of 22.7%, which is slower than the revenue growth rate. Sales expenses were 770 million yuan (up 17.2% YoY), and management expenses increased by 2.7% YoY, both significantly lower than the revenue growth rate of 23.6% [3]. - Research and development expenses decreased significantly from 410 million yuan in the previous year to 170 million yuan, a reduction of 60.1% YoY, reflecting a focus on optimizing key product development [3]. Future Outlook - The company is expected to see revenue growth rates of 13.03%, 20.90%, and 18.98% for 2024, 2025, and 2026, respectively. Net profit growth rates are projected at 122.85%, 120.45%, and 122.48% for the same years, with corresponding earnings per share (EPS) of 0.04, 0.08, and 0.18 yuan per share [4].

Financial Performance - The company's revenue for Q3 2024 reached ¥461,884,945.51, representing a 13.23% increase year-over-year[2] - Net profit attributable to shareholders was ¥51,423,214.50, a significant increase of 296.25% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was ¥47,006,089.12, up 216.37% year-over-year[2] - The company reported a net profit of ¥109,679,781.38, a 149.86% increase compared to the previous year[5] - The net profit for Q3 2024 was ¥109,679,781.38, a significant recovery from a net loss of ¥219,963,187.35 in the same period last year, marking a turnaround of approximately 149.8%[12] - Operating profit for the quarter was ¥130,476,262.44, compared to an operating loss of ¥214,762,325.22 in Q3 2023, indicating a substantial improvement[12] - Total operating revenue for Q3 2024 reached CNY 1,384,454,586.25, an increase of 23.6% compared to CNY 1,119,748,100.35 in the same period last year[11] - The company reported a total comprehensive income of ¥113,765,759.91, a significant improvement from a loss of ¥205,905,094.78 in the same quarter last year[12] - The basic earnings per share for Q3 2024 was ¥0.14, recovering from a loss per share of ¥0.20 in the previous year[12] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date reached ¥447,539,961.30, showing a remarkable increase of 4,858.75%[5] - Cash flow from operating activities increased to ¥447,539,961.30, a recovery from a negative cash flow of ¥9,404,569.09 in the previous year[13] - The company's investment activities generated a net cash outflow of ¥330,534,996.03, compared to a net outflow of ¥105,600,912.14 in Q3 2023[13] - The cash flow from investing activities was negative at ¥-330,534,996.03, primarily due to increased purchases of financial products[5] - The financing activities resulted in a net cash outflow of ¥46,749,451.42, a decrease from a net inflow of ¥167,186,491.72 in the same quarter last year[14] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,955,163,114.25, reflecting a 12.24% increase from the end of the previous year[2] - Total assets rose to CNY 3,955,163,114.25, compared to CNY 3,523,881,824.92, marking a growth of 12.2%[10] - Total liabilities increased to CNY 829,239,882.21 from CNY 513,199,460.61, reflecting a rise of 61.6%[10] - The company's equity attributable to shareholders was ¥2,987,635,531.04, which is a 3.02% increase compared to the previous year-end[2] - The company's equity attributable to shareholders reached CNY 2,987,635,531.04, up from CNY 2,899,985,004.21, an increase of 3%[10] Accounts and Inventory - Accounts receivable increased by 50.72% to ¥212,996,731.27, primarily due to increased revenue[5] - Accounts receivable increased to ¥212,996,731.27 from ¥141,321,772.09, reflecting a growth of approximately 50.6%[8] - Inventory increased to ¥186,547,469.30 from ¥167,488,565.20, showing a rise of about 11.4%[8] - Total current assets increased to ¥2,560,459,703.31 from ¥2,186,481,431.88, representing a growth of approximately 17.0%[8] Research and Development - Research and development expenses decreased by 60.06% to ¥165,585,331.02, focusing on key advantageous products[5] - R&D expenses for the quarter were CNY 165,585,331.02, significantly lower than CNY 414,550,119.50 in the previous year, indicating a decrease of 60%[11] Other Information - The company has not disclosed any new product or technology developments in this report[7] - There are no updates on market expansion or mergers and acquisitions mentioned in the report[7] - The report does not provide specific future outlook or performance guidance[7] - Cash and cash equivalents rose to ¥1,127,202,068.77 from ¥1,047,046,980.60, an increase of about 7.7%[8] - Cash and cash equivalents at the end of the quarter were CNY 524,953,469.88, compared to CNY 210,528,776.20, indicating a significant increase of 149.5%[10] - The company recorded a tax expense of ¥14,988,316.43, compared to ¥5,301,048.28 in Q3 2023, reflecting an increase in taxable income[12] - Long-term equity investments slightly increased to ¥106,283,284.19 from ¥104,515,740.18, a growth of about 1.7%[8] - The company reported a significant increase in trading financial assets to ¥955,695,869.43 from ¥713,826,223.29, a growth of approximately 33.9%[8] - Deferred income tax assets decreased to CNY 23,495,302.19 from CNY 25,729,709.70, a decline of 8.7%[10]

该议案已经公司审计委员会审议通过，议案内容详见同日发布于巨潮资讯网 （www.cninfo.com.cn）的《2024 年第三季度报告》。 北京奥赛康药业股份有限公司（以下简称"公司"）第六届董事会第十六次会议 于 2024 年 10 月 20 日以电子邮件、专人送达的方式通知各位董事，会议于 2024 年 10 月 30 日以现场表决的方式在南京江宁科学园科建路 699 号 A 楼 2218 会议室召 开。本次会议应到董事 9 人，实到董事 9 人。公司监事、高级管理人员列席了会议。 本次会议符合《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）等法律、行政法规、部门规章、规范性文件和 《公司章程》的相关规定。 会议由董事长陈庆财先生主持，经与会董事认真审议，一致形成如下决议： 一、审议通过《关于公司 2024 年第三季度报告的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 证券代码：002755 证券简称：奥赛康 公告编号：2024-033 北京奥赛康药业股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真 ...

证券代码：002755 证券简称：奥赛康 公告编号：2024-034 北京奥赛康药业股份有限公司 第六届监事会第十三次会议决议公告 北京奥赛康药业股份有限公司（以下简称"公司"）第六届监事会第十三次会议 于 2024 年 10 月 20 日以电子邮件、专人送达的方式通知各位监事，会议于 2024 年 10 月 30 日以现场表决的方式在南京江宁科学园科建路 699 号 A 楼 2218 会议室召 开。本次会议应到监事 3 人，实到监事 3 人。本次会议符合《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 等法律、行政法规、部门规章、规范性文件和《公司章程》的相关规定。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载，误导性陈述或重大遗漏。 会议由监事会主席陈靖先生主持，经与会监事认真审议，一致形成如下决议： 一、审议通过《关于公司 2024 年第三季度报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 《公司第六届监事会第十三次会议决议》 特此公告。 北京奥赛康药业股份有限公司监事会 经审核，监事会认为：董事会编制和审 ...

一、药品基本情况 项目名称：马来酸奈拉替尼片 证券代码：002755 证券简称：奥赛康 公告编号：2024-032 北京奥赛康药业股份有限公司 关于子公司马来酸奈拉替尼片 获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）的全资子公司江苏奥赛 康药业有限公司（以下简称"子公司"）于近日收到国家药品监督管理局（以下 简称"药监局"）核准签发的马来酸奈拉替尼片《药品注册证书》，相关情况如下： 于早期 HER2 乳腺癌患者的扩展辅助治疗药物。国家药品监督管理局于 2020 年 4 月批准马来酸奈拉替尼片进口上市，商品名为贺俪安®，NERLYNX®，规格为 40mg，适用于人类表皮生长因子受体 2（HER2）阳性的早期乳腺癌成年患者， 在接受含曲妥珠单抗辅助治疗之后的强化辅助治疗。 乳腺癌居全球恶性肿瘤发病率第一位，是女性恶性肿瘤患者死亡的主要原因， 也是中国女性发病率最高的癌症。奈拉替尼作为全球首个乳腺癌强化辅助口服治 疗药物已经被国际国内多个权威指南推荐。早期乳腺癌中 HER2+患者约占 20~3 ...

证券代码：002755 证券简称：奥赛康 公告编号：2024-031 北京奥赛康药业股份有限公司 关于对控股子公司增资的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、增资情况概述 AskGene Limited（以下简称"AskGene"）是北京奥赛康药业股份有限公司（以 下简称"公司"）的控股子公司，公司由全资子公司江苏奥赛康药业有限公司通过 其全资子公司Sea Glory Group Limited持有AskGene已发行股份。 Sea Glory Group Limited拟以现金2.2亿元人民币向AskGene增资，上海泰福 谨通企业管理合伙企业（有限合伙）拟以现金3,000万元人民币向AskGene增资。 本次增资完成后，公司持有AskGene已发行股份数的比例由59.07%提高到62.86%， 公司仍为AskGene的控股股东，AskGene仍将纳入公司合并报表范围。本次增资 资金主要用于AskGene日常运营、研发等。 公司第六届董事会第十五次会议审议通过了《关于对控股子公司增资的议 案》，本次增资事项不构成关联交易，也不构成《上市公司重大 ...

证券代码：002755 证券简称：奥赛康 公告编号：2024-030 公司董事会同意对控股子公司 AskGene Limited 增资，并授权公司管理层签 署、修订、接受与此次增资相关的协议、交易文件、法律文件或相关的交易安排。 具体内容详见公司同日披露于《证券时报》、《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）的《关于对控股子公司增资的公告》（公告编号：2024- 031）。 表决结果：9 票同意，0 票反对，0 票弃权。 二、备查文件 北京奥赛康药业股份有限公司 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）第六届董事会第十五次会 议于 2024 年 9 月 27 日以电子邮件、专人送达的方式通知各位董事。会议于 2024 年 10 月 8 日以现场表决的方式在南京江宁科学园科建路 699 号 A 楼 3102 会 议室召开。本次会议应到董事 9 人，实到董事 9 人。公司监事、高级管理人员列 席了会议。本次会议符合《中华人民共和国公司法》（ ...